和铂医药与Cullinan Oncology就B7H4x4-1BB双特异性抗体签订授权及合作协议
EQS 新闻 via SEAPRWire.com / 2023-02-14 / 11:12 UTC+8 和铂医药与Cullinan Oncology就B7H4x4-1BB双特异性抗体签订授权及合作协议 HBM7008是一款针对B7H4x...
Novotech at ESMO Congress 2022 – New Data Shows 100% Oncology Trials Growth in APAC
SYDNEY, Sep 5, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has […]
Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China
SYDNEY, Jun 6, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, is sponsoring the […]
Novotech Sponsors Pre-ASCO China Summit Expert Panels on Early Phase Oncology Trials and Regulatory Strategy for China and US
SYDNEY, Jun 2, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, has sponsored expert […]
Edison Oncology和冠科美博（Apollomics）宣布EO1001(APL-122) I/IIa 期临床试验中首例患者接受治疗
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Oct 1, 2021 – (亚太商讯 via SEAPRWire.com) – Edison...
Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial
MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 – (ACN Newswire via SEAPRWire.com) – Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the […]
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
FOSTER CITY, Calif. and HANGZHOU, China and MENLO PARK, CA, Feb 10, 2021 – (ACN Newswire) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of […]
Sino Biopharmaceutical Announces 2020 Third Quarterly Results
HONG KONG, Nov 30, 2020 – (ACN Newswire) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate […]